US Pharma MarketingEpicrispr, Vaderis secure pivotal study funding for rare disease assets
Epicrispr, Vaderis secure pivotal study funding for rare disease assets is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Epicrispr and Vaderis have secured $90m and $152m, respectively, to take their rare disease drugs to pivotal clinical development.
Source: Pharmaceutical Technology